arGentis Autoimmune Europe

arGentis Autoimmune is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases through the induction of oral tolerance. The company's lead candidate, ARG201, is an orally administered purified bovine type I collagen designed to treat systemic sclerosis (scleroderma) by modulating the immune system's response to collagen. By utilizing the body's natural mechanism of oral mucosal tolerance, arGentis aims to provide disease-modifying treatments that are safer and more targeted than traditional immunosuppressants. The company is also exploring applications for its technology in other collagen-related autoimmune conditions such as rheumatoid arthritis.